Zoetis Inc. (NYSE:ZTS) Shares Purchased by Raub Brock Capital Management LP

Raub Brock Capital Management LP boosted its position in shares of Zoetis Inc. (NYSE:ZTS) by 2.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 88,807 shares of the company’s stock after acquiring an additional 1,832 shares during the period. Zoetis comprises 3.1% of Raub Brock Capital Management LP’s investment portfolio, making the stock its 21st biggest holding. Raub Brock Capital Management LP’s holdings in Zoetis were worth $14,469,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. State Street Corp raised its holdings in Zoetis by 0.5% during the third quarter. State Street Corp now owns 19,779,344 shares of the company’s stock worth $3,864,488,000 after purchasing an additional 95,856 shares in the last quarter. Geode Capital Management LLC raised its stake in Zoetis by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 10,427,760 shares of the company’s stock worth $2,030,813,000 after acquiring an additional 185,364 shares in the last quarter. Mizuho Securities USA LLC lifted its position in Zoetis by 13,726.9% in the third quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock valued at $950,524,000 after acquiring an additional 4,829,815 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Zoetis by 5.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,896,106 shares of the company’s stock valued at $761,221,000 after acquiring an additional 194,542 shares in the last quarter. Finally, Clearbridge Investments LLC grew its holdings in shares of Zoetis by 5.8% during the second quarter. Clearbridge Investments LLC now owns 3,044,384 shares of the company’s stock worth $527,774,000 after purchasing an additional 166,517 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on ZTS shares. Stifel Nicolaus reduced their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. JPMorgan Chase & Co. upped their price target on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Leerink Partners assumed coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price objective on the stock. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Finally, UBS Group initiated coverage on Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. One analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $211.89.

Zoetis Stock Down 2.0 %

Shares of NYSE ZTS opened at $166.01 on Friday. The stock has a market capitalization of $74.90 billion, a price-to-earnings ratio of 31.20, a price-to-earnings-growth ratio of 2.51 and a beta of 0.89. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.53. The firm has a 50-day moving average price of $170.93 and a 200 day moving average price of $179.95. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.12. The firm had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. Zoetis’s revenue was up 11.6% on a year-over-year basis. During the same period in the previous year, the firm posted $1.36 earnings per share. Equities research analysts anticipate that Zoetis Inc. will post 5.91 EPS for the current fiscal year.

Zoetis Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.20%. The ex-dividend date is Tuesday, January 21st. This is an increase from Zoetis’s previous quarterly dividend of $0.43. Zoetis’s dividend payout ratio is 32.52%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.